ATLANTA and HOLLISTON, Mass., Dec. 8, 2015 /PRNewswire/ — Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that Executive Vice President and Chief Medical Officer Saverio La Francesca, MD will moderate and speak at the World Stem Cell Summit during a secession entitled “Regenerative Engineering and Bio-Materials” on Saturday, December 12, 2015 at 2:00 p.m. ET. The conference will be held at the Hyatt Regency in Atlanta, GA.
HART’s cell frame technology utilizes the patient’s own stem cells combined with its proprietary scaffold to restore organ function in the airways and esophagus. HART recently reported significant improvements in their Gen2 product implants.
About Dr. Saverio La Francesca:
Dr. La Francesca is a cardiothoracic surgeon with over 25 years of academic, clinical surgical practice, and innovative research in the cardiovascular, thoracic transplantation, cardiac assist device, and regenerative medicine fields. Previously he worked with the Dept. of Cardiovascular Surgery and Transplantation at DeBakey Heart and Vascular Center at the Houston Methodist Hospital, where he developed the current surgical and perfusion techniques for thoracic organ procurement and preservation. He was also an attending surgeon at the Department of Cardiopulmonary Transplantation at the Texas Heart Institute in Houston, Texas. Dr. La Francesca holds UNOS certifications as heart transplant surgeon and lung transplant surgeon and is a certified surgeon for the use of the HeartMate and the Jarvik 2000 left ventricular assist devices.
About World Stem Cell Summit (worldstemcellsummit.com)
The World Stem Cell Summit, produced by the Genetics Policy Institute (GPI), is the largest interdisciplinary, networking meeting of stem cell science and regenerative medicine stakeholders, uniting the diverse community. With the overarching purpose of fostering biomedical research, funding, and investments targeting cures, the Summit is the single conference charting the future of this burgeoning field. Featuring more than 200 renowned international speakers and 65 hours of in-depth programming, the World Stem Cell Summit unites, educates and harmonizes the global stem cell community.
About HART: (www.hartregen.org)
Harvard Apparatus Regenerative Technology (HART) makes bioengineered organ implants for life-threatening conditions. Our technology platform is to be used to restore function in the esophagus and the airways (trachea and bronchus). HART is completing further large-animal studies to refine our technology platform with the goal of filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in 2016, seeking to initiate clinical trials for one of our three product candidates. Our first-generation trachea technology was used in five adult human trachea transplants approved under compassionate use exemptions, but none of our products are yet approved for marketing by a government regulatory authority.
Twitter: Investor Relations @HART_IR_Team
Catalyst Global LLC
David Collins, Tanya Kamatu
SOURCE Harvard Apparatus Regenerative Technology, Inc.